|
|
|
|
| LEADER |
03657nam a2200361 u 4500 |
| 001 |
EB000945893 |
| 003 |
EBX01000000000000000739483 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
150303 r ||| eng |
| 100 |
1 |
|
|a McKinney, Ross
|
| 245 |
0 |
0 |
|a White paper
|h Elektronische Ressource
|b potential conflict of interest in the production of drug compendia
|c Duke Evidence-based Practice Center, Duke Center for Clinical Health Policy Research ; Ross McKinney, Amy P. Abernethy, David B. Matchar, Jane L. Wheeler
|
| 246 |
3 |
1 |
|a Potential conflict of interest in the production of drug compendia
|
| 260 |
|
|
|a Rockville, Maryland
|b Agency for Healthcare Research and Quality
|c April 27, 2009, 2009
|
| 300 |
|
|
|a 1 PDF file (vii, 104 pages)
|b illustration
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Conflict of Interest
|
| 653 |
|
|
|a United States
|
| 653 |
|
|
|a Pharmacopoeias as Topic
|
| 700 |
1 |
|
|a Abernethy, Amy Pickar
|e [author]
|
| 700 |
1 |
|
|a Matchar, David B.
|e [author]
|
| 700 |
1 |
|
|a Wheeler, Jane L.
|e [author]
|
| 710 |
2 |
|
|a Duke University Evidence-based Practice Center
|
| 710 |
2 |
|
|a United States
|b Agency for Healthcare Research and Quality
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Technology assessment
|
| 500 |
|
|
|a Title from PDF title page
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK253242
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a The pages that follow provide: (1) a description of compendia processes, delineating points at which conflict of interest may arise; (2) an ethical framework for evaluating the potential presence and influence of conflict of interest in compendia; (3) results of an investigation into the policies and practices of four specific compendia (those officially approved for use in making Medicare coverage determinations) with regard to conflict of interest; and (4) a discussion of the adequacy of compendia approaches to conflict of interest, problems with conflict of interest that have been reported, and opportunities for minimizing conflict of interest in the compendia to ensure an objective and impartial system. Results presented in this white paper do not constitute a critique of existing compendia.
|
| 520 |
|
|
|a This white paper, which was commissioned by the Agency for Healthcare Research and Quality (AHRQ), with sponsorship from the Centers for Medicare & Medicaid Services (CMS), explores the concern that conflict of interest may potentially influence the inclusion/exclusion decisions, editorial processes, production, and content of current drug compendia. Drug compendia--pharmacopoeia providing information on drugs, their effectiveness, safety, toxicity, and dosing - are frequently used to determine whether a medication has a role in the treatment of a particular disease; these roles include both therapeutic uses approved by the U.S. Food and Drug Administration (FDA) and off-label indications. Policy enactments have also resulted in use of the compendia to inform reimbursement decisions made by CMS and other third-party payers.
|
| 520 |
|
|
|a Rather, the investigators explored specific questions with the intention of: identifying, if warranted, potential areas for improvement; assisting AHRQ and CMS in developing a systematic approach to the understanding of conflict-of-interest-related bias in drug compendia; and contributing to the effort to hone the compendia system such that it provides a digest of accurate, timely, unbiased, and complete evidence to clinicians as a reference for clinical decision-making
|